• Flatiron’s 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research.

NEW YORK--(BUSINESS WIRE)--May 22, 2025-- Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)."

The updated release reads:

FLATIRON HEALTH ANNOUNCES RESEARCH TO BE PRESENTED AT ASCO 2025

• Flatiron’s 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research.

Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron’s commitment to advancing cancer research and align with this year’s ASCO theme, “Driving Knowledge to Action: Building a Better Future,” by delivering critical evidence to inform and improve patient care.

“AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,” said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. “Our research accepted at this year’s ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.”

Highlights include:

• a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer
• an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer
• an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings

Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels.

Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131.

Abstracts and Poster Presentations
Racial and ethnic differences in biomarker testing for targetable alterations among patients with HR+ HER2- metastatic breast cancer (mBC)
Catherine Keane, Gene G. Ho, Samantha Reiss, Melissa Estevez, Katherine Harrison, Anca Marinescu, Olive Mbah
Breast Cancer—Metastatic
Poster board: 63
Abstract number: 1084

Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)
Erin Fidyk, Patrick Ward, Melissa Estevez, Konstantin Krismer, John Ritten, Anca Marinescu, Aaron B. Cohen
Breast Cancer—Local/Regional/Adjuvant
Poster board: 148
Abstract number: 555

Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): insights by PTEN status
Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca
Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li
Genitourinary—Prostate, Testicular, and Penile
Poster board: 295
Abstract number: 5096

Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data
Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz
Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal
Quality Care/Health Services Research
Poster board: 436
Abstract number: 11097

Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer
Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago
Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster board: 199
Abstract number: 8078

Molecular residual disease (MRD) in solid tumors
Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center
Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol
Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster board: 486b
Abstract number: TPS3186

Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US)
Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals
Online publication only

Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study
Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists
Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia
Online publication only

A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC)
Partner: Incyte
Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu
Online publication only

A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens
Partners: Merck & Co, MSD UK, Mayo Clinic
Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh
Online publication only

Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting
Partners: Cleveland Clinic, Merck KGaA, EMD Serono
Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter
Online publication only

Concordance of response-based clinical trial and machine learning–generated real-world end points
Partner: Genentech
Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee
Online publication only

Real-world progression-free survival of CDK4/6 inhibitors (CDK4/6i) plus an aromatase inhibitor (AI) in HR+/HER2− MBC in US routine clinical practice
Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center
Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky
Online publication only

Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse
Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center
Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour
Online publication only

About Flatiron

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250522021439/en/

Nina Toor
press@flatiron.com

Source: Flatiron Health